The Effect of Bromelain (Anaheal) on Clinical and Para-Clinical Parameters in Hospitalized COVID-19 Patients

• DOI: 10.18502/acta.v59i12.8066
• Publication Date: 2021-12-18T13:51:41Z
• Authors: Alireza Jahangiri...; Ashkan Omidi; Kurdistan Sharifz...; Seyed Bashir Mirt...; Farzad Peyravian; Saeid Safari; Maedeh Sadat Jafa...; Seyed Hadi Mirhas...; Behrooz Farzanegan
• Keywords: Bromelain

The severity of COVID-19 disease and its mortality may be due to a localized vascular problem owing the activation bradykinin B1 receptors on endothelial cells in lungs that occur following inflammation. Bromelain acts as an anti-inflammatory factor can lower level serum tissues. Patients with novel coronavirus (COVID-19) referred Masih Daneshvari Hospital Tehran were included study after providing full explanations obtaining written consent. 40 patients mild moderate symptoms randomly divided into control group (No: 20) sample 20). In group, dose 200 mg bromelain was given every 8 hours. placebo capsules administered exactly at above intervals. Clinical paraclinical factors (including SaO2, RR body temperature, MAP, HR, CRP, ESR, AST, ALT, Bil, BUN, Cr, WBC, Lymph, LDH, Plt evaluated regular basis for up five days. results using t-test SPSS21 software. After treatment, (Bromelain) indicated significant improvement RR, WBC Lymphocyte count (P<0.05). Other did not have difference group. causes some clinical such respiratory parameters para items hospitalized patients, so it promising treatment. Furthered evaluation larger groups is recommended.